Working… Menu

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00162500
Recruitment Status : Withdrawn
First Posted : September 13, 2005
Last Update Posted : November 10, 2010
Vaxil Therapeutics Ltd.
Information provided by:
Hadassah Medical Organization

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Primary Completion Date : No date given
Study Completion Date : No date given